These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21544715)

  • 21. Novel anti-platelet agents: focus on thrombin receptor antagonists.
    de Souza Brito F; Tricoci P
    J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease-activated receptors as targets for antiplatelet therapy.
    Hamilton JR
    Blood Rev; 2009 Mar; 23(2):61-5. PubMed ID: 18644663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring oral antiplatelet therapy: is it justified?
    Ang L; Mahmud E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):485-96. PubMed ID: 19124443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
    Leonardi S; Tricoci P; Becker RC
    Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New antithrombotic drugs.
    Gross PL; Weitz JI
    Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protease-activated receptors in cardiovascular health and diseases.
    Shah R
    Am Heart J; 2009 Feb; 157(2):253-62. PubMed ID: 19185631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombin receptors and their antagonists: an update on the patent literature.
    Cirino G; Severino B
    Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease.
    Verheugt FW
    J Cardiovasc Risk; 1996 Apr; 3(2):229-32. PubMed ID: 8836868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin-activated receptors: promising targets for cancer therapy?
    García-López MT; Gutiérrez-Rodríguez M; Herranz R
    Curr Med Chem; 2010; 17(2):109-28. PubMed ID: 19941475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys.
    Chintala M; Strony J; Yang B; Kurowski S; Li Q
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2143-9. PubMed ID: 20798382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
    Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
    Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?
    Geisler T; Gawaz M; Steinhubl SR; Bhatt DL; Storey RF; Flather M
    Pharmacol Ther; 2010 Aug; 127(2):95-107. PubMed ID: 20570595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.